E-viri
PDF
Recenzirano
Odprti dostop
-
Migden, Michael R; Rischin, Danny; Schmults, Chrysalyne D; Guminski, Alexander; Hauschild, Axel; Lewis, Karl D; Chung, Christine H; Hernandez-Aya, Leonel; Lim, Annette M; Chang, Anne Lynn S; Rabinowits, Guilherme; Thai, Alesha A; Dunn, Lara A; Hughes, Brett G.M; Khushalani, Nikhil I; Modi, Badri; Schadendorf, Dirk; Gao, Bo; Seebach, Frank; Li, Siyu; Li, Jingjin; Mathias, Melissa; Booth, Jocelyn; Mohan, Kosalai; Stankevich, Elizabeth; Babiker, Hani M; Brana, Irene; Gil-Martin, Marta; Homsi, Jade; Johnson, Melissa L; Moreno, Victor; Niu, Jiaxin; Owonikoko, Taofeek K; Papadopoulos, Kyriakos P; Yancopoulos, George D; Lowy, Israel; Fury, Matthew G
The New England journal of medicine, 07/2018, Letnik: 379, Številka: 4Journal Article
Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was associated with the expected spectrum of adverse events.
